930,367 Shares in Novo Nordisk A/S $NVO Acquired by Contrarius Group Holdings Ltd

Contrarius Group Holdings Ltd acquired a new position in Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, HoldingsChannel.com reports. The fund acquired 930,367 shares of the company’s stock, valued at approximately $47,337,000. Novo Nordisk A/S makes up about 2.3% of Contrarius Group Holdings Ltd’s portfolio, making the stock its 13th biggest holding.

Other hedge funds have also recently modified their holdings of the company. Godfrey Financial Associates Inc. bought a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at $25,000. WealthCollab LLC increased its position in Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after buying an additional 260 shares in the last quarter. American National Bank & Trust purchased a new stake in Novo Nordisk A/S in the fourth quarter worth about $28,000. Maseco LLP purchased a new stake in Novo Nordisk A/S in the fourth quarter worth about $29,000. Finally, Jackson Grant Investment Advisers Inc. purchased a new stake in Novo Nordisk A/S in the fourth quarter worth about $29,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $42.93 on Monday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The company has a market cap of $191.66 billion, a P/E ratio of 10.08, a P/E/G ratio of 3.83 and a beta of 0.78. The firm’s fifty day moving average is $41.62 and its two-hundred day moving average is $46.17. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The company had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. As a group, analysts anticipate that Novo Nordisk A/S will post 3.46 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on NVO shares. Nordea Equity Research cut shares of Novo Nordisk A/S to a “hold” rating in a research note on Tuesday, February 24th. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Kepler Capital Markets cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Wolfe Research assumed coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 26th. They set a “peer perform” rating on the stock. Finally, Sanford C. Bernstein assumed coverage on shares of Novo Nordisk A/S in a research note on Wednesday, March 18th. They set an “outperform” rating and a $175.00 target price on the stock. Four research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Hold” and an average target price of $65.56.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: TD Cowen raised its 2030 GLP-1 sales forecast to $150 billion and expects Novo Nordisk to remain one of the two dominant leaders alongside Eli Lilly, implying continued long-term demand for obesity and diabetes therapies. GLP-1 Sales Forecast Jumps To $150 Billion By 2030
• Positive Sentiment: Novo Nordisk is expanding internationally as only 1%–2% of global patients currently use obesity drugs, suggesting a large untapped market if pricing and access improve over time. Novo And Lilly Push Beyond US As Only 1%-2% Use Obesity Drugs Globally
• Positive Sentiment: Novo Nordisk announced a clinical supply agreement with Veru for a Phase 2b obesity trial testing Wegovy in combination with enobosarm, giving the company another potential path to extend its obesity franchise. Novo Nordisk Tests Wegovy Combinations In Older Adults With Veru Trial
• Neutral Sentiment: Investor attention is elevated ahead of Novo Nordisk’s ADA conference data releases and June 7 R&D event, which could create volatility depending on pipeline updates and clinical readouts. Novo Nordisk gains as investors position for ADA data and June 7 R&D event
• Neutral Sentiment: Novo Nordisk is also getting broad market attention as a “trending stock,” but that reflects heightened investor interest rather than a clearly stock-moving fundamental update. Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.